COI code: MSC16_061
Paper Language: English
How to Download This Paper
For Downloading the Fulltext of CIVILICA papers please visit the orginal Persian Section of website.
Authors Identifying clinical response to B-interferon in multiple sclerosis patientsMahbubeh Rojhannezhad - PhD student of genetics department of genetics, Faculty of biological sciences, Tarbiat modares university
Abdorreza Naser Moghadasi - Tehran University of Medical Sciences, Department of Neurology
Abbas Nikravesh - Department of Medical Biotechnology & Molecular Sciences, Faculty of Medicine, Bojnord University
Mehrdad Behmanesh - Department of genetics, Faculty of biological sciences, Tarbiat modares university
Abstract:Background and Objective: Multiple sclerosis (MS) is a chronic disease that involves an immune-mediated process in which an abnormal response of the body’s immune system is directed against the central nervous system (CNS). β-interferon (βIFN) is one of the first major therapies to control exacerbations in MS but it is only partially effective. Several Studies aim to identify molecular signature of βIFN clinical response in MS patients and also biomarkers that allow early identification of treatment failure or ideally even predict non-responder status. Materials and Methods: In this study we have reviewed several studies and analyzed microarray data (GSE5574) investigating gene expression patterns from longitudinal PBMC samples taken from patients prior to βIFN therapy and chronic post-treatment.Results and Conclusion: Analysis of the data showed that, not surprisingly genes related to pathways like interferon signaling, cytokine signaling and immune response are differentially expressed. Type I IFN-signalling pathway was the most significantly associated with the non-responder phenotype. Interferons (IFNs) are inducible cytokines with potent antiviral and anti-proliferative effects. In several autoimmune disorders such as rheumatoid arthritis, Sjögren s syndrome and also in a subgroup of MS patients (RRMS) IFN type I gene expression has been reported to be upregulated. Therefor it seems that common etiological factors and pathogenetic pathways operate in these autoimmune disorders. To validate this pathway as a prediction marker for βIFN clinical response further data analysis is needed.
Keywords:multiple sclerosis, β-interferon , clinical response
COI code: MSC16_061
how to cite to this paper:If you want to refer to this article in your research, you can easily use the following in the resources and references section:
Rojhannezhad, Mahbubeh; Abdorreza Naser Moghadasi; Abbas Nikravesh & Mehrdad Behmanesh, 2019, Identifying clinical response to B-interferon in multiple sclerosis patients, 16th iranian international congress on multiple sclerosis, مشهد, انجمن ام اس ايران, https://www.civilica.com/Paper-MSC16-MSC16_061.htmlInside the text, wherever referred to or an achievement of this article is mentioned, after mentioning the article, inside the parental, the following specifications are written.
First Time: (Rojhannezhad, Mahbubeh; Abdorreza Naser Moghadasi; Abbas Nikravesh & Mehrdad Behmanesh, 2019)
Second and more: (Rojhannezhad; Naser Moghadasi; Nikravesh & Behmanesh, 2019)
For a complete overview of how to citation please review the following CIVILICA Guide (Citation)
The University/Research Center Information:
Type: state university
Paper No.: 25985
in University Ranking and Scientometrics the Iranian universities and research centers are evaluated based on scientific papers.
Research Info Management
Export Citation info of this paper to research management softwares
New Related Papers
- Tumefactive brain MRI lesions in NMOSD patient: report of a case
- New therapeutic approach by G2013 in experimental model of multiple sclerosis
- HEADACHE in pregnancy:diagnosis and management
The Above articles are recently indexed in the related subjects
Iran Scientific Advertisment Netword
Share this paper
WHAT IS COI?
COI is a national code dedicated to all Iranian Conference and Journal Papers. the COI of each paper can be verified online.